Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Primary Peritoneal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02012192
What this trial is testing

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Medical University Innsbruck 133
Testing effectiveness (Phase 2)Study completedNCT06173037
What this trial is testing

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Who this might be right for
Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
RemeGen Co., Ltd. 43
Testing effectiveness (Phase 2)Looking for participantsNCT05538091
What this trial is testing

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPARP Inhibitor+1 more
Ronald Buckanovich 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT04781088
What this trial is testing

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+4 more
Floor Backes, MD 38
Early research (Phase 1)Study completedNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT06028932
What this trial is testing

Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Who this might be right for
Ovarian Carcinoma
Yale University 20
Testing effectiveness (Phase 2)Ended earlyNCT00023907
What this trial is testing

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Ended earlyNCT00004037
What this trial is testing

Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT03314740
What this trial is testing

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

Who this might be right for
Ovarian Neoplasms
Mario Negri Institute for Pharmacological Research 123
Testing effectiveness (Phase 2)Study completedNCT03093155
What this trial is testing

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Yale University 78
Large-scale testing (Phase 3)Looking for participantsNCT07546500
What this trial is testing

Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Who this might be right for
Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 420
Testing effectiveness (Phase 2)Study completedNCT00499252
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian Carcinoma
Gynecologic Oncology Group 51
Early research (Phase 1)Active Not RecruitingNCT03907527
What this trial is testing

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+31 more
Precigen, Inc 71
Testing effectiveness (Phase 2)Study completedNCT00617773
What this trial is testing

Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Recepta Biopharma 31
Large-scale testing (Phase 3)Looking for participantsNCT06161025
What this trial is testing

Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Solid Cancer
Daiichi Sankyo 860
Testing effectiveness (Phase 2)Study completedNCT00428610
What this trial is testing

Chemotherapy Treatment for Patients With Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Eli Lilly and Company 103
Testing effectiveness (Phase 2)Ended earlyNCT05538624
What this trial is testing

Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Who this might be right for
Neoplasm, OvarianFallopian Tube CancerPrimary Peritoneal Cavity Cancer+5 more
Avenge Bio, Inc 14
Early research (Phase 1)Ended earlyNCT01202890
What this trial is testing

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Carcinoma+1 more
New Mexico Cancer Research Alliance 1
Testing effectiveness (Phase 2)UnknownNCT03188159
What this trial is testing

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube Cancer
National University Hospital, Singapore 36
Testing effectiveness (Phase 2)Study completedNCT02272790
What this trial is testing

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
AstraZeneca 95
Next Page